Drug Trial Radar · NCT06819215
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
188
Planned (sponsor's estimate)
Start
Oct 30, 2024
Primary completion
Dec 30, 2025
Study completion Mar 30, 2026
Sponsor
- Lead sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Shandong Cancer Hospital and Institute
- First posted
- Feb 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Conditions
- Cancer
- Neoplasms
- Neoplasms, Breast
- Tumor
- PARP
- Ovarian Neoplasms
- Prostatic Cancer
- Pancreatic Cancer
- Breast Cancer
- Biliary Cancer
- Colorectal Cancer
Interventions
VB15010Drug
Oral PARP1 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of subjects with adverse events/serious adverse eventsTime frame: From time of Informed Consent to 30+7 days post last dose
- The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.Time frame: At the end of Cycle 1(each cycle is 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital of Shandong First Medical university
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.